X0306 4 2017-09-13 0 0000849636 RespireRx Pharmaceuticals Inc. RSPI 0001236365 MANUSO JAMES S J C/O RESPIRERX PHARMACEUTICALS INC. 126 VALLEY ROAD, SUITE C GLEN ROCK NJ 07452 1 1 0 0 President and CEO Common Stock 2017-09-13 4 P 0 1097 A 74252 D Common Stock Warrants (right to buy) 6.83 2017-09-13 4 P 0 2195 A 2015-09-15 2020-09-30 Common Stock 2195 2195 D Common Stock Options (to purchase shares of Common Stock) 1.45 2017-12-09 4 J 0 608704 A 2022-12-09 Common Stock 608704 608704 D Common Stock Options (to purchase shares of Common Stock) 2 2022-06-30 Common Stock 50000 50000 D Common Stock Options (to purchase shares of Common Stock) 3.9 2022-01-17 Commmon Stock 75000 75000 D COmmon Stock Warrants (right to buy) 6.83 2016-04-07 2020-09-30 Common Stock 36578 36578 D Common Stock Warrants (right to buy) 6.5 2016-02-04 2019-02-04 Common Stock 8093 8093 D Common Stock Options (to purchase shares of Common Stock) 7.3775 2021-03-31 Common Stock 81539 81539 D Common Stock Options (to purchase shares of Common Stock) 6.396 2025-08-18 Common Stock 15634 15634 D Common Stock Options (to purchase shares of Common Stock) 6.396 2025-08-18 Common Stock 246154 246154 D Dr. Manuso purchased shares and warrants in a private transaction for an aggregate of $5,000, or $4.56 per unit, with each unit consisting of one share and warrants to purchase two additional shares of the Company's common stock. On December 9, 2017, Dr. Manuso forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $878,360. On that date, the Company granted to Dr. Manuso options to purchase 608,704 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $878,360. These Common Stock Options vested upon issuance. These Common Stock Options vested upon issuance. These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested. The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016. These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested. These Common Stock Options vested in three installments: 50 percent on August 18, 2015 (the grant date), 25 percent on February 18, 2016, and 25 percent on August 18, 2016, and are all currently vested. /s/ James S. Manuso 2017-12-12